Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group. Englund JA, et al. Among authors: larussa p. Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5. Vaccine. 2013. PMID: 24103895 Free PMC article. Clinical Trial.
Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
Halsey NA, Griffioen M, Dreskin SC, Dekker CL, Wood R, Sharma D, Jones JF, LaRussa PS, Garner J, Berger M, Proveaux T, Vellozzi C; Hypersensitivity Working Group of the Clinical Immunization Safety Assessment Network; Broder K, Setse R, Pahud B, Hrncir D, Choi H, Sparks R, Williams SE, Engler RJ, Gidudu J, Baxter R, Klein N, Edwards K, Cano M, Kelso JM. Halsey NA, et al. Vaccine. 2013 Dec 9;31(51):6107-12. doi: 10.1016/j.vaccine.2013.09.066. Epub 2013 Oct 8. Vaccine. 2013. PMID: 24120547
The postmarketing safety profile of varicella vaccine.
Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA. Sharrar RG, et al. Among authors: larussa p. Vaccine. 2000 Nov 22;19(7-8):916-23. doi: 10.1016/s0264-410x(00)00297-8. Vaccine. 2000. PMID: 11115716
Effectiveness of varicella vaccine in children infected with HIV.
Son M, Shapiro ED, LaRussa P, Neu N, Michalik DE, Meglin M, Jurgrau A, Bitar W, Vasquez M, Flynn P, Gershon AA. Son M, et al. Among authors: larussa p. J Infect Dis. 2010 Jun 15;201(12):1806-10. doi: 10.1086/652798. J Infect Dis. 2010. PMID: 20441519 Free PMC article.
Eczema vaccinatum as an adverse event following exposure to vaccinia virus: case definition & guidelines of data collection, analysis, and presentation of immunization safety data.
Nell P, Kohl KS, Graham PL, LaRussa PS, Marcy SM, Fulginiti VA, Martin B, Trolin I, Norton SA, Neff JM; Brighton Collaboration Vaccinia Virus Vaccine Adverse Event Working Group for Eczema Vaccinatum. Nell P, et al. Among authors: larussa ps. Vaccine. 2007 Aug 1;25(31):5725-34. doi: 10.1016/j.vaccine.2007.02.085. Epub 2007 May 2. Vaccine. 2007. PMID: 17532547 No abstract available.
166 results